Expression databases - Resources for pharmacogenomic R&D

Pharmacogenomics

Volumn 1, Issue 3, 2000, Pages 281-288

  Furness, L Mike ^a   Henrichwark, Sven ^a,b   Egerton, Mark ^a,b  

^a Botanic House   (United Kingdom)

^b Department of Life Sciences   (United States)

Author keywords

Drug development; Expression database; Lead optimisation; Microarrays; Pharmacogenetics; Pharmacogenomics; Proteomics; Single nucleotide polymorphisms (SNP); Target discovery; Toxicology; Transcript profiling

Indexed keywords

ANIMAL; FACTUAL DATABASE; GENE EXPRESSION; GENETICS; HUMAN; PHARMACOGENETICS; REVIEW; STATISTICS;

ANIMALS; DATABASES, FACTUAL; GENE EXPRESSION; HUMANS; PHARMACOGENETICS;

EID: 0034252328     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.1.3.281     Document Type: Review

References (27)

1. BAILEY DS, BONDAR A, FURNESS LM: Pharmacogenomics - it's not just pharmacogenetics. Curr. Opin. Biotech. (1998) 9:595-601.
2. LIPINSKI C: Pfizer's CASPROP database. (1999) Personal communication.
3. SKOLNICK J, FETROW JS: From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotech. (2000) 18:34-39. •• A well written and comprehensive overview of the latest developments in prediction of protein structure and function from genomic sequence information. It reinforces the argument that genomic sequence alone will only give us a partial picture of the full diversity of subcellular biology.
4. DICKSON D: Gene estimate rises as US and UK discuss freedom of access. Nature (1999) 401:311.
5. WALKER MG, VOLKMUTH W, SPRINZAK E, HODGSON H, KLINGLER T: Prediction of gene function by genome-scale expression analysis: prostate cancer-associated genes. Genome Res. (1999) 9:1198-1203. • A great introduction into the power of statistics applied to large sets of cDNA sequence data to identify annotations for novel genes.
6. MEYER UA, ZANGER UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann. Rev. Pharmacol. Toxicol. (1997) 37:269-296. •• This is an excellent review of the polymorphic nature of drug metabolising enzymes, providing readers with a good introduction to the area and a concise summary of the data up to 1997.
7. BARROSO I, GURNELL M, CROWLEY VEF et al.: Dominant negative mutations in human PPAR associated with severe insulin resistance, diabetes mellitus and hypertension. Nature (1999) 402:880-883.
8. BUSCHER R, HERRMANN V, INSEL PA: Human adrenoreceptor polymorphisms: evolving recognition of importance. Trends Pharmacol. Sci. (1999) 20:94-99.
9. VU-DAC N, CHOPIN-DELANNOY S, GERVOIS P et al.: The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J. Biol. Chem. (1998) 273:25713-25720.
10. UHL GR, SORA I, WANG Z: The μ opiate receptor as a candidate gene for pain; polymorphisms, variations in expression, nociception and opiate responses. Proc. Natl. Acad. Sci. USA (1999) 96:7752-7755. •• A short article which shows the interactions of gene expression, genetic polymorphism and physiological responses in opiate receptors as a microcosm of the complexity in biology.
11. QUACKENBUSH J, LIANG F, HOLT I, PERTEA G, UPTON J: The TIGR Gene Indices: reconstruction and representation of expressed gene sequences. Nucleic Acids Res. (2000) 28:141-145.
12. LIANG P, PARDEE AB: Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science (1992) 257:967-971.
13. LIPSHUTZ RJ, FODOR SPA, GINGERAS TR, LOCKHART DJ: High density synthetic oligonucleotide arrays. Nature Genet. (1999) (Microarray Supplement) 21:20-24.
14. BROWN PO, BOTSTEIN D: Exploring the new world of the genome with DNA microarrays. Nature Genet. (1999) (Microarray Supplement) 21:10.
15. BOWTELL D: Options available - from start to finish-for obtaining expression data from microarrays. Nature Genet. (1999) (Microarray Supplement) 21:25-32. • Although it is already becoming a little dated, this article gives a good comparison of the ranges of technology platforms and techniques that are currently applied to gene expression analyses.
16. GERHOLD D, RUSHMORE T, CASKEY CT: DNA chips: promising toys have become powerful tools. Trends Biochem. Sci. (1999) 24:168-173.
17. SCHENA M, HELLER RA, THIERAULT T, KONRAD K, LACHENMEIER E, DAVIS RW: Microarrays: biotechnology's discovery platform for functional genomics. Trends Biotech. (1998) 16:301-306.
18. ZWEIGER G: Knowledge discovery in gene-expression-microarray data: mining the information output of the genome. Trends Biotech. (1999) 17:429-436.
19. FARR S, DUNN RT: Concise review: gene expression applied to toxicology. Toxicol. Sci. (1999) 50:1-9.
20. SHIMKETS RA, LOWE DG, TAI JT-N et al.: Gene expression analysis by transcript profiling coupled to gene database query. Nature Biotech. (1999) 17:798-803.
21. O'FARRELL PH: High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. (1975) 250:4007-4021.
22. PAGE MJ, AMESS B, TOWNSEND RR et al.: Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc. Natl. Acad. Sci. USA (1999) 96:12589-12594.
23. ANDERSON NL, ANDERSON NG: Proteome and proteomics: new technologies, new concepts and new words. Electrophoresis (1998) 19:1853-1861.
24. ANDERSON L, SEILHAMER J: A comparison of selected mRNA and protein abundances in human liver. Electrophoresis (1997) 18:533-537.
25. GYGI SP, ROCHON Y, FRANZA BR, AEBERSOLD R: Correlation between protein and mRNA abundance in yeast. Mol. Cell Biol. (1999) 19:1720-1730.
26. ALBALA JS, HUMPHERY-SMITH I: Array-based proteomics: high-throughput expression and purification of IMAGE consortium cDNA clones. Curr. Opin. Mol. Ther. (1999) 1:680-684.
27. DAVIES H, LOMAS L, AUSTEN B: Profiling of amyloid beta peptide variants using SELDI ProteinChip® arrays. BioTechniques (1999) 27:1258-1261.